ATOS Atossa Therapeutics, Inc.
Healthcare$4.96-0.20%ClosedMarket Cap: $42.7M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
1.40
P/S
0.00
EV/EBITDA
-0.28
DCF Value
$4.34
FCF Yield
-78.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-84.9%
ROA
-99.2%
ROIC
-129.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-9.9M | $-9.6M | $— | — |
| Q4 null | $0.00 | NaN% | $-11.4M | $-10.9M | $— | — |
| FY null | $0.00 | NaN% | $-37.1M | $-34.8M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-9.3M | $-8.7M | $— | — |
| Q2 null | $0.00 | NaN% | $-9.0M | $-8.4M | $— | — |
| Q1 null | $0.00 | NaN% | $-7.4M | $-6.7M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-7.2M | $-6.3M | $— | — |
| FY null | $0.00 | -Infinity% | $-27.6M | $-25.5M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-6.4M | $-7.2M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-7.1M | $-6.0M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-7.0M | $-5.9M | $— | — |
| Q4 2023 | $18.0K | -77.8% | $-9.0M | $-7.8M | $-0.93 | — |